Oftentimes, companies are expected to do their due diligence prior to submissions. At one time, as part of such due diligence, a medium-sized pharma company located in the EU was seeking assistance with HEOR activities for a new chemical product to be used in urology. The client was looking for an experienced vendor to create an SLR in keeping with the requirements of NICE submission, specifying that the speed of execution and cost effectiveness remain within the quality framework; this is where Bioviser made an appearance. Of note, the client had a tight deadline for the NICE submission, which, if unmet, would have caused a direct revenue impact on the product.
After thoroughly understanding the client’s needs and expectations, Bioviser jumped into action and set up a remote team that consisted of a group of analysts along with clinical and stats experts. The primary role of this group was to provide strategic inputs and guidance on a suitable development course for the new product to follow in the US.